DOCSLIB.ORG

B and T Cell-Mediated Central Nervous System Demyelinating Disease: Underlying Mechanisms and Clinical Perspectives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B and T Cell-Mediated Central Nervous System Demyelinating Disease: Underlying Mechanisms and Clinical Perspectives B and T cell-mediated central nervous system demyelinating disease: underlying mechanisms and clinical perspectives Jamie van Langelaar No parts of this thesis may be reproduced or transmitted in any form by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system, without permission in writing from the author. The research for this thesis was performed within the framework of the Erasmus MC Postgraduate School Molecular Medicine. The studies described in this thesis were performed at the Department of Immunology and the Department of Neurology, Erasmus MC, Rotterdam, the Netherlands. The studies were financially supported by the Dutch MS Research Foundation and Zabawas. The printing of this thesis was supported by Erasmus MC. ISBN: 978-94-91811-28-9 Cover design: Karien van Langelaar Lay-out: Bibi van Bodegom & Daniëlle Korpershoek Printing: Ridderprint | www.ridderprint.nl Copyright © 2021 by Jamie van Langelaar. All rights reserved. B and T Cell-mediated Central Nervous System Demyelinating Disease: Underlying mechanisms and clinical perspectives B en T cel-gemedieerde demyeliniserende ziekte van het centrale zenuwstelsel: Onderliggende mechanismen en klinische perspectieven Thesis to obtain the degree of Doctor from the Erasmus University Rotterdam by command of the rector magnicus Prof.dr. F.A. van der Duijn Schouten and in accordance with the decision of the Doctoral Board The Public defense will be held on Tuesday 16 March 2021 at 10:30 hrs by Jamie van Langelaar born in East London, South Africa DOCTORAL COMMITTEE Promotors Prof.dr. P. Katsikis Prof.dr. P.A.E. Sillevis Smitt Other members Prof.dr. B.C. Jacobs Prof.dr. J.D. Laman Prof.dr. R.W. Hendriks Copromotor Dr. M.M. van Luijn CONTENTS CHAPTER 1 9 General introduction CHAPTER 2 39 T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention Brain 2018;141;1334-1349 CHAPTER 3 69 Brain-homing CD4+ T cells display glucocorticoid-resistant features in multiple sclerosis Neurology, Neuroimmunology and Neuroinflammation 2020;7 CHAPTER 4 89 Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis Annals of Neurology 2019;86:264-278 CHAPTER 5 115 The association of Epstein-Barr virus infection with CXCR3+ B-cell development in multiple sclerosis: impact of immunotherapies European Journal of Immunology 2020; Epub ahead of print CHAPTER 6 133 Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses Brain Communications 2020; Epub ahead of print CHAPTER 7 155 General discussion ADDENDUM 181 List of abbreviations 182 Summary 184 Samenvatting 187 Acknowledgements 191 Curriculum vitae 198 PhD portfolio 199 List of publications 201 Chapter 1 General introduction 1_ 1- General introduction GENERAL INTRODUCTION 1 Every day the human body encounters various pathogens such as bacteria and viruses. If these pathogens break through the initial physical and chemical barriers of the body, the immune system is recruited to eliminate them. To achieve this, the immune system uses tightly regulated innate and adaptive defense mechanisms. Rapid recognition and elimination of the pathogen is mediated by the innate immune response, while the adap- tive immune response is slower but more specic and generates immunological memory for a quicker response if re-exposure occurs. The intricate balance between eector and regulatory immune cells ensures an optimal immune response. This balance also prevents immune responses against self-antigens through a phenomenon called immune toler- ance. However, the interplay between intrinsic (genetic) and extrinsic (environmental) fac- tors likely causes breakdown of self-tolerance, eventually resulting in autoimmune disease. Adaptive immunity (B and T cells) plays a fundamental, but yet incompletely understood role in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). MS and NMOSD are inammatory and demyelinating diseases of the central nervous system (CNS) that are mediated by autoimmune-related processes. In this chapter, we introduce how B and T cells develop and interact in healthy individuals and what could trigger particular subsets to become pathogenic instead of protective in such patients. This sets the stage for the current thesis, which addresses the underlying mechanisms and clinical impact of human B and T cells on inammatory CNS demyelinating disease. ADAPTIVE IMMUNITY B and T cells initially develop in the bone marrow and originate from hematopoietic stem cells (HSCs) committed to the lymphoid lineage [1]. Depending on the cytokine milieu and distinct transcription factors [1-3], lymphoid progenitor cells will either remain in the bone marrow to mature into B cells or migrate to the thymus to mature into T cells. During these processes, highly specic and unique B- and T-cell receptors are generated, making it possible to recognize a large variety of antigens. Both central and peripheral tol- erance checkpoints are exploited to prevent recognition of self-antigens and to promote the development of functional subsets with non-self-reactive receptors [4]. Such B and T cells recirculate in the blood until an antigen is encountered within lymphoid organs. Upon encounter with antigens, B and T cells are activated and dierentiate into eector and memory cells in order to remove the pathogen through antibody-mediated humoral and cytotoxic cellular immunity [5, 6]. To reach these eector and memory stages, B and T 11 Chapter 1 cells undergo a series of well-regulated developmental steps, which are further explained below. B-cell development and eector functions In the bone marrow, HSC-derived precursors develop into immature B cells with a B cell receptor (BCR) that is generated by random gene recombination of their immunoglobulin (Ig) heavy and light chain loci, known as V(D)J rearrangements [7, 8]. Two main central tolerance mechanisms ensure that immature B cells expressing high anity BCRs for self-antigens are removed. Receptor editing occurs when a self-reactive BCR is expressed during the early stages of B-cell development and certies that this specicity is lost through a second round of V(D)J rearrangements [9]. This mechanism involves the removal of an autoreactive BCR by deleting the self-reactive light-chain gene and replacing it with another sequence. If receptor editing fails, clonal deletion in the bone marrow removes self-reactive B cells [9]. The cells that survive these checkpoints exit the bone marrow and enter the circulation as transitional B cells (CD38high CD24highIgM+IgD+), which then further dierentiate into naive mature B cells (CD38-/dimIgM+CD27- IgD+; Fig. 1) with a functional BCR [7, 8]. At this particular stage, peripheral tolerance mechanisms including apoptosis, anergy and T regulatory cell (Treg)-mediated suppression are important to control autore- active B cells that have escaped negative selection in the bone marrow [10]. Within secondary lymphoid organs such as the lymph nodes, mature naive B cells encounter antigens via the BCR, internalize, process and present these antigens on human leukocyte antigen (HLA) class II molecules to CD4+ T cells [11]. This can initiate either germi- nal center (GC)-dependent or –independent dierentiation of naive B cells into memory B cells and antibody-secreting cells (ASCs; Fig. 1) [12, 13]. In GC-dependent responses B cells receive signals from CD4+ T follicular helper (Tfh) cells via CD40 ligand (CD40L[CD40]), CD28 (CD80/CD86) and interleukin (IL)-21 to undergo clonal expansion, class switch recombina- tion and somatic hypermutations of the VH genes [6]. During class switch recombination, the constant region of the BCR Ig heavy chain is replaced by other isotypes that have vary- ing properties and functions. Somatic hypermutations take place at the variable regions of both the Ig heavy and light chains and comprises of single-nucleotide exchanges, deletions and point mutations [14]. Both these processes increase the anity of B cells for antigens. Somatic hypermutations in the GC can lead to formation of self-reactive B cells as well, however the tolerance mechanisms involved here to regulate their removal remains poorly understood [15]. Strong HLA-II antigen presentation and co-stimulation via CD40L/CD40 are key processes for maintaining peripheral tolerance [9, 16]. B cells that survive peripheral tolerance checkpoints and enter GCs develop into class switched IgG+, IgA+ or IgE+ memory B cells and long-lived plasma cells (CD38highCD27highCD138+) [17, 18]. There is also generation of non-class switched IgM+ memory B cells [19, 20]. This can occur 12 General introduction in a GC-independent manner via the marginal zone in the spleen giving rise to natural eector B cells (CD27+IgM+IgD+) or in a GC-dependent manner that results in the devel- 1 opment of ‘IgM-only’ (CD27+IgM+IgD-) B cells (Fig. 1) [20]. Furthermore, GC-independent responses can lead to the generation of short-lived plasmablasts (CD38highCD27high) when B cells interact with CD4+ T cells in extra-follicular regions [12, 13]. Memory B cells function to act as antigen-presenting cells (APCs) and secrete pro- or anti-inammatory cytokines [21, 22]. Whereas, ASCs consist of both short-lived plasmablasts and long-lived plasma cells + /dim + + + Central Peripheral tolerance tolerance Short-lived PB dim + + high high /dim high high - - + + + Short-/long-lived PC + dim high high + + /dim
Load more

Recommended publications
  • How This Paralympian Won Gold in London
    The Official Magazine of MS Australia – ACT/NSW/VIC www.msaustralia.org.au/actnswvic ISSN 1833-8941 Print Post Approved: Summer 2012 PP 255003/08108 Overcome Carol depression Spotlight on Cooke the NDIS How this Paralympian Gifts you can won gold in London give yourself EMERGING 2012 GO FOR GOLD: TREATMENTS See page 36 New oral medications for inspiring stories www.facebook.com/MSAustralia http://twitter.com/MS_Australia www.youtube.com/MSSocietyAustralia Editor: Toni Eatts Publisher: Multiple Sclerosis Limited 38 ABN: 66 004 942 287 Website: www.msaustralia.org.au/actnswvic Frequency: Published quarterly in March, June, September, December Advertising enquiries: Tel: (02) 9646 0725, Fax: (02) 9643 1486, Email: [email protected] Design: Byssus, (02) 9482 5116, www.byssus.com.au Photographs: The stock images appearing in Intouch are sourced from Thinkstock.com 19 Cover: Ben Vella, Shoot Everything Photography Printing: Webstar Print MS Australia – ACT/NSW/VIC ACT Gloria McKerrow House 117 Denison Street Deakin ACT 2600 Tel: (02) 6234 7000 Fax: (02) 6234 7099 NSW Studdy MS Centre 80 Betty Cuthbert Dr Lidcombe NSW 2141 Tel: (02) 9646 0600 Fax: (02) 9643 1486 Victoria The Nerve Centre 54 Railway Road Blackburn VIC 3130 Tel: (03) 9845 2700 Fax: (03) 9845 2777 MS ConnectTM (information and services): 1800 042 138 (free call) Regional offices: Visit www.msaustralia.org.au/actnswvic and click on ‘Contact Us’ Privacy Policy: Visit www.msaustralia.org.au/ actnswvic for our full policy document ISSN: 1833-8941 14 Disclaimer: Information and articles contained in Intouch are intended to provide useful and accurate information of a general nature for the reader but are not intended to be a substitute 12 for legal or medical advice.
    [Show full text]
  • WCN19 Journal Posters Part 2 Revised V1
    JNS-0000116542; No. of Pages 131 ARTICLE IN PRESS Journal of the Neurological Sciences (2019) xxx–xxx Contents lists available at ScienceDirect Journal of the Neurological Sciences journal homepage: www.elsevier.com/locate/jns WCN19 Journal Posters Part 2 revised_V1 WCN19-2260 WCN19-2269 Poster shift 01 - Channelopathies /neuroethics /neurooncology / Poster shift 01 - Channelopathies /neuroethics /neurooncology / pain - Part I /sleep disorders - Part I /stem cells and gene therapy - pain - Part I /sleep disorders - Part I /stem cells and gene therapy - Part I /stroke /training in neurology - Part I and traumatic brain Part I /stroke /training in neurology - Part I and traumatic brain injury injury Numb chin syndrome- The first finding in metastatic malignancy Results of surgical treatment in patients with moyamoya disease considering CT-perfusion imaging study N. Mustafayev, A. Bayrakoglu, F. Ilgen Uslu, M. Kolukısa Bezmialem University, Neurology, Istanbul, Turkey O. Harmatinaa, V. Morozb, I. Skorokhodab, I. Tyshb, N. Shahinb,R. Hanemb, U. Maliarb a Numb chin syndrome (NCS) is a sensory neuropathy of the SI «Romodanov Institute of Neurosurgery of NAMS of Ukraine», mental nerve, which is accompanied by hypoesthesia and paresthe- Neuroradiology Department, Kyiv, Ukraine b sia of the jaw and lower lip. Although being well known in neurology SI «Romodanov Institute of Neurosurgery of NAMS of Ukraine», practice, most of the physicians who have not experienced this Emergency Department of Vascular Neurosurgery, Kyiv, Ukraine phenomenon are unaware of this phenomenon since it is rare and can be confused with somatic complaints. This case report aims to Aim point out that NCS may be the first sign and symptom of metastatic To improve the results of surgical treatment of patients with cancers in patients who are not diagnosed.
    [Show full text]
  • Acting Positively: Strategic Implications of the Economic Costs of Multiple Sclerosis in Australia Report by Access Economics Pty Limited
    ACTING POSITIVELY: STRATEGIC IMPLICATIONS OF THE ECONOMIC COSTS OF MULTIPLE SCLEROSIS IN AUSTRALIA REPORT BY ACCESS ECONOMICS PTY LIMITED FOR MULTIPLE SCLEROSIS AUSTRALIA WINTER 2005 Acting positively: strategic implications of the economic costs of MS in Australia TABLE OF CONTENTS Acknowledgements and disclaimer i Glossary of common abbreviations ii EXECUTIVE SUMMARY iii 1. Prevalence and socioeconomic impacts 9 1.1 Epidemiology and aetiology....................................................................................................9 1.1.1 What is MS? ...................................................................................................................9 1.1.2 Aetiology.......................................................................................................................10 1.1.3 Mortality and co-morbidity............................................................................................12 1.2 Treatment and management ................................................................................................14 1.2.1 Prevention and early intervention.................................................................................14 1.2.2 Pharmacological management.....................................................................................15 1.2.3 Psychosocial and other health interventions................................................................15 1.2.4 Other and alternative interventions ..............................................................................16 1.3
    [Show full text]
  • The Role of Serum Lipid Profile and Comorbidities in the Onset and Progression of Multiple Sclerosis
    The role of serum lipid profile and comorbidities in the onset and progression of multiple sclerosis By Prudence Tettey BSc (Human Biology); MPhil (Medical Microbiology) A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy (Medical Studies) Menzies Institute for Medical Research December, 2015 Declaration of originality This thesis contains no material which has been accepted for any degree or diploma by the University or any other institution, except by way of background information and duly acknowledged in the thesis, and to the best of my acknowledge and belief, no material previously published or written by another person, except where due acknowledgment is made in the text of the thesis. Signature 8/12/2015 ……………………………….. ……………………………. Prudence Tettey Date II Statement of authority to access This thesis may be available for loan. Copying of any part of this thesis is prohibited for two years from the date this statement was signed; after that time, limited copying is permitted in accordance with the Australian Copyright Act of 1968. Signature 8/12/2015 ……………………………. ………………………………….. Prudence Tettey Date III Statement regarding published work contained in thesis The publishers of the papers contained in this thesis hold the copyright for that content, and access to the material should be sought from the respective journals. The remaining non published content of the thesis may be made available for loan and limited copying and communication in accordance with the Copyright Act 1968. Signature 8/12/2015 ……………………………… …………………………… Prudence Tettey Date IV Statement of Co-authorship This thesis includes papers for which Prudence Tettey (PT) is not sole author.
    [Show full text]
  • Curriculum Vitae State University of New York at Stony Brook Health
    Curriculum Vitae State University of New York at Stony Brook Health Sciences Center Name: Patricia K. Coyle Birthplace: New York City Mailing Address: HSC T12, Room 20 Stony Brook, NY 11794-8121 Home Telephone: (631) 473-8932 Work Telephone: (631) 444-8188 Higher Education (Including Internship, Residency & other formal professional training) From To Degree and Date Institution, Location & Field 9/1966 6/1970 B.S. 1970 Fordham University, NY Honors Program, Summa Cum Laude in Cursu Honorum 7/1970 6/1974 M.D. 1974 Johns Hopkins, MD Medicine, AOA 7/1974 6/1975 Internship Cornell, NY Hospital Medicine 7/1975 6/1977 Residency Johns Hopkins, MD Neurology 7/1977 6/1978 Chief Resident Johns Hopkins, MD Neurology 7/1978 6/1980 Research Fellow Johns Hopkins, MD Neuroimmunology and Neurovirology 1 Certification & Licensure (ECFMG, FLEX, National & Professional Boards & Licenses) Date Agency January 1980 American Board of Psychiatry & Neurology (ABPN) 2004 Recertification, ABPN July 1980 New York State Medical License #124559 Appointments (Academic Appointments) Date Title Status* Institution & Location 7/80 – 6/88 Ass’t. Prof. S SUNY – Stony Brook 7/88 – 3/93 Assoc. Prof. T SUNY – Stony Brook 3/93 – present Professor T SUNY – Stony Brook 10/88 – 4/89 Acting Chair SUNY – Stony Brook 10/91 – 6/92 Acting Chair SUNY – Stony Brook 3/03 – 9/12 Acting Chair SUNY – Stony Brook 10/12 – present Vice Chair SUNY – Stony Brook (Clinical Affairs) *Status: Voluntary (V), Salaried (S), Tenured (T) Other Appointments Date Title Status Institution & Location 7/80 – present Attending Neurologist S University Medical Center, Stony Brook 7/80 – 1995 Attending Neurologist V Northport VAMC 8/87 – 1993 Consultant V Central Islip Psychiatric Center 2 Professional Practice & Services Date Activity Location Institution Affiliation(s) 7/1980 – present Attending Neurologist Stony Brook SUNY – Stony Brook Univ.
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update Horizon
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: July 2014 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290201000006C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 July 2014 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]
  • Neuroradiology
    2013 RSNA (Filtered Schedule) Sunday, December 01, 2013 10:30-12:00 PM • VSPD11 • Room: S100AB • Pediatric Radiology Series: Pediatric Neuroimaging I 10:45-12:15 PM • SSA15 • Room: N226 • Neuroradiology/Head and Neck (Temporal Bones) 10:45-12:15 PM • SSA16 • Room: N227 • Neuroradiology/Head and Neck (Vascular Disease of the Head and Neck) 10:45-12:15 PM • SSA17 • Room: N229 • Neuroradiology (Parkinson's Disease) 12:30-01:00 PM • LL-NRS-SUA • Room: Lakeside Learning Center • Neuroradiology/Head and Neck - Sunday Posters and Exhibits (12:30pm - 1:00pm) 01:00-01:30 PM • LL-NRS-SUB • Room: Lakeside Learning Center • Neuroradiology/Head and Neck - Sunday Posters and Exhibits (1:00pm - 1:30pm) 02:00-03:30 PM • RC105 • Room: S406B • Traumatic Brain Injury 02:00-03:30 PM • RC106 • Room: E451A • Eye and Orbit 02:00-03:30 PM • RC108 • Room: E353B • Imaging of the Traumatized Spine (Traditional) (An Interactive Session) 02:00-03:30 PM • RC111 • Room: S505AB • Multi-modal Imaging Workup for Alzheimer's Disease, Parkinson's Disease, and Related Disorders: Case-based App... 02:00-03:30 PM • RC118 • Room: E353A • Interactive Game: Interactive Quiz Cases in Neuro-oncologic Imaging 02:00-03:30 PM • RC120 • Room: E352 • Radiographic Evaluation of the Post-Radiotherapy Brain Monday, December 02, 2013 07:15-08:15 AM • SPSH20 • Room: E451B • Hot Topic Session: Concussion and Traumatic Brain Injury 08:30-10:00 AM • MSRO21 • Room: S103AB • BOOST: Head and Neck-Anatomy and Contouring (An Interactive Session) 08:30-10:00 AM • RC206 • Room: E450A • Head and Neck
    [Show full text]
  • Second Joint Meeting
    Second Joint Meeting May 27–30 May 30 www.actrims.org ENVIRONMENTAL RISK FACTORS [email protected] IN MULTIPLE SCLEROSIS Basic and Clinical Issues in FUTURE ACTRIMS MEETINGS Multiple Sclerosis Research 2010 San Antonio, Texas — June 5 Saturday, May 30, 2009 Offered in cooperation with the Consortium of Multiple Sclerosis Centers, June 2–5 Hyatt Regency Atlanta 2011 Atlanta, Georgia Amsterdam, The Netherlands — October 19–22 Offered jointly with ECTRIMS and LACTRIMS The 14th annual ACTRIMS meeting is jointly sponsored by the University of Maryland School of Medicine and the National Multiple Sclerosis Society. ACTRIMS meetings are held in collaboration with the National Multiple Sclerosis Society and the MS Society of Canada. Contents Welcome Letter ................................. 3 ACTRIMS Committees ............................ 4 Disclosures .................................... 5 Program Information ............................. 7 Schedule of Events .............................. 9 Agenda ....................................... 1 0 List of Poster Presentations ........................ 1 3 Featured Speaker Biographies ...................... 1 9 Summaries and Abstracts Oral Presentations ■ CMSC-ACTRIMS Donald Paty Memorial Lecture ............ 23 ■ Session 1: EBV and Other Viruses ....................... 23 ■ Session 2: Basic and Clinical Issues in Multiple Sclerosis Research .................................. 26 ■ Session 3: Vitamin D and MS .......................... 27 ■ Session 4: Gene-Environment Interactions and MS Susceptibility
    [Show full text]
  • TAG Mail 2020 (January - June)
    TAG Mail 2020 (January - June) Cumulative Listing of Reports, Publications, Medication Safety Information and Papers of Interest TAG Mail – 23 April 2020 COVID-19 RESOURCES & ARTICLES OF INTEREST Please see the cumulative listing for COVID-19 resources included in last week’s TAG Mail AUSTRALIAN ACSQHC - COVID-19 Medicines management: Position statements on medicine-related issues - link - Potential medicines to treat COVID-19 - link AHHA - From the Frontline Virtual Conference: Virtual care and telehealth in action, a COVID-19 Special Event, 24 April 2020 9:00-16:00 - link CEC -COVID-19 medication related issues including Clinician Information about experimental medicines, and weekly medication shortage updates - link CSANZ - Position statement: Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic - link - Position Statement: The Evaluation of Patients Presenting With Suspected Acute Coronary Syndromes during the COVID-19 Pandemic - link Department of Health - Factsheets summarising the interim arrangement for e-prescribing to support telehealth are available for prescribers, pharmacists and consumers NCCET (National COVID-19 Clinical Evidence Taskforce) - Section 5: Antivirals and other disease modifying treatments - link - Management of patients with suspected mild COVID-19 - link NSW Health - Image-based prescriptions - link - COVID-19 Critical Intelligence Unit Updates – link Pharmacy Board AHPRA - No place for racism in healthcare - link - COVID-19 update
    [Show full text]
  • Oxford American Handbook of Neurology Published and Forthcoming Oxford American Handbooks
    Oxford American Handbook of Neurology Published and Forthcoming Oxford American Handbooks Oxford American Handbook of Clinical Medicine Oxford American Handbook of Anesthesiology Oxford American Handbook of Clinical Dentistry Oxford American Handbook of Clinical Diagnosis Oxford American Handbook of Clinical Pharmacy Oxford American Handbook of Critical Care Oxford American Handbook of Emergency Medicine Oxford American Handbook of Geriatric Medicine Oxford American Handbook of Nephrology and Hypertension Oxford American Handbook of Neurology Oxford American Handbook of Obstetrics and Gynecology Oxford American Handbook of Oncology Oxford American Handbook of Otolaryngology Oxford American Handbook of Pediatrics Oxford American Handbook of Physical Medicine and Rehabilitation Oxford American Handbook of Psychiatry Oxford American Handbook of Pulmonary Medicine Oxford American Handbook of Rheumatology Oxford American Handbook of Sports Medicine Oxford American Handbook of Surgery Oxford American Handbook of Neurology Edited by Sid Gilman William J. Herdman Distinguished University Professor of Neurology University of Michigan School of Medicine Ann Arbor, Michigan with Hadi Manji Sean Connolly Neil Dorward Neil Kitchen Amrish Mehta Adrian Wills 1 3 Oxford University Press, Inc. publishes works that further Oxford University’s objective of excellence in research, scholarship and education. Oxford New York Auckland Cape Town Dar es Salaam Hong Kong Karachi Kuala Lumpur Madrid Melbourne Mexico City Nairobi New Delhi Shanghai Taipei Toronto With offi ces in Argentina Austria Brazil Chile Czech Republic France Greece Guatemala Hungary Italy Japan Poland Portugal Singapore South Korea Switzerland Thailand Turkey Ukraine Vietnam Copyright © 2010 by Oxford University Press, Inc. Published by Oxford University Press Inc. 198 Madison Avenue, New York, New York 10016 www.oup.com Oxford is a registered trademark of Oxford University Press First published 2010 All rights reserved.
    [Show full text]
  • TAG Mail – 2 April 2020 COVID-19 RESOURCES & ARTICLES of INTEREST Please See the Cumulative Listing for COVID-19 Resources Included in Last Week’S TAG Mail
    TAG Mail 2020 (January - June) Cumulative Listing of Reports, Publications, Medication Safety Information and Papers of Interest TAG Mail – 2 April 2020 COVID-19 RESOURCES & ARTICLES OF INTEREST Please see the cumulative listing for COVID-19 resources included in last week’s TAG Mail Australian - AHPRA Pharmacy Board: -- Responding to COVID-19: Changes to presenting-in-person requirements – link -- Online uploads for documents - link - NPS - Being medicinewise during COVID-19 - link - NSW Health - COVID-19 clinical trial guidance - link - SHPA COVID-19 discussion forum – now open to all healthcare professionals (Non-SHPA member health professionals interested in joining the forum should email [email protected]) -- Some recent topics of discussion: Aboriginal and Torres Strait Islander COVID resources, COVID-19 Emergency Supply of Medicines Quick Guides (NSW, TAS, VIC, SA, WA), COVID-19 and Pregnancy/Lactation, Use of Patients Own Medicines & Hospital Supplied items, Oncology and Haematology + COVID-19 resources and Smoking cessation resource. - TGA -- No evidence to support intravenous high-dose vitamin C in the management of COVID-19 - link -- COVID-19 testing in Australia - information for health professionals - link -- Warning to consumers about self-test kits - link -- COVID-19 test kits included on the ARTG for legal supply in Australia - link International - International Society for Quality in Health Care (ISQua) --Webinar Recording: The COVID-19 Response in Italy: Learning from the front line - link Canada -University of Toronto
    [Show full text]
  • THE RESEARCH ISSUE How the World’S Brightest Minds Are Tackling Multiple Sclerosis
    AUTUMN 2018 ISSN 1833-8941 Print Post Approved: 100003204 THE RESEARCH ISSUE How the world’s brightest minds are tackling multiple sclerosis 1 intouch autumn 2018 www.ms.org.auwww.ms.org.au www.ms.org.au autumn 2018 intouch PB › CEO’s message WELCOME to your first Intouch magazine of continued investment and collaboration in 2018 – a special edition we’ve dedicated to research and advocacy crucial. multiple sclerosis research, in accordance The goals of treatment are to slow, stop with the theme of this year’s World MS Day. and reverse disability – and in these pages, But first, the magazineitself. We’ve heard you can read all about how the global the MS community’s feedback on its look, research community is tackling the challenge, feel and readability, and we’ve redesigned as well as hear stories from people who’ve it with those areas in mind. We thank you experienced and contributed to the advances sincerely for your comments and hope you in multiple sclerosis research. like the new look as much as we do. We stand by our ongoing commitment We’re very much looking forward to to multiple sclerosis research, we celebrate Publisher: Multiple Sclerosis Limited celebrating World MS Day this year, along what it’s achieved so far, and we look forward ABN: 66 004 942 287 with its theme of research ‘bringing us closer’. to the day the tireless work of the scientific Editor: Antony Giummarra Since inception we have been committed community has cured this disease. Advertising enquiries: [email protected] Privacy Policy: Visit www.ms.org.au to providing services to focus on helping for our full document people affected by multiple sclerosis and their ISSN: 1833-8941 families aim for the best possible outcomes.
    [Show full text]